{
    "clinical_study": {
        "@rank": "53693", 
        "arm_group": [
            {
                "arm_group_label": "BI 207127 + Faldaprevir", 
                "arm_group_type": "Experimental", 
                "description": "Tablets/capsules"
            }, 
            {
                "arm_group_label": "Moxifloxacin (Avalox\u00ae)", 
                "arm_group_type": "Active Comparator", 
                "description": "Tablets"
            }, 
            {
                "arm_group_label": "BI 207127 placebo + Faldaprevir placebo", 
                "arm_group_type": "Experimental", 
                "description": "Tablets/capsules"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the effect of multiple doses of BI 207127\n      combined with faldaprevir on cardiac safety parameters in healthy subjects"
        }, 
        "brief_title": "Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Healthy male and female subjects\n\n          -  Subjects must be able to understand and comply with study requirements\n\n          -  Age =18 and =55 years\n\n          -  BMI range: =18.5 and =29.9 kg/m2\n\n        Exclusion criteria:\n\n        - any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965431", 
            "org_study_id": "1241.40", 
            "secondary_id": "2013-002741-11"
        }, 
        "intervention": [
            {
                "arm_group_label": "BI 207127 + Faldaprevir", 
                "description": "Medium dose oral administration", 
                "intervention_name": "BI 207127", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 207127 placebo + Faldaprevir placebo", 
                "intervention_name": "BI 207127 placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 207127 placebo + Faldaprevir placebo", 
                "intervention_name": "Faldaprevir placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 207127 + Faldaprevir", 
                "description": "Medium dose oral administration", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Moxifloxacin (Avalox\u00ae)", 
                "intervention_name": "Moxifloxacin (Avalox\u00ae)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ingelheim", 
                    "country": "Germany"
                }, 
                "name": "1241.40.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Female and Male Subjects. Randomised, Placebo Controlled, Single-blind, Three-period Crossover Phase-I-study With Moxifloxacin as Positive Control", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Largest mean placebo-corrected QTcN change from baseline between 1 to 24 hours on Day 1 for the combination therapy", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965431"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Largest mean placebo-corrected QTcN change from baseline between 1 to 6 hours on Day 1 for the moxifloxacin treatment", 
                "safety_issue": "No", 
                "time_frame": "6 hours"
            }, 
            {
                "measure": "Largest mean placebo-corrected HR (heart rate) change from baseline between 1 to 24 hours on Day 1 for the combination therapy", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Smallest mean placebo-corrected HR (heart rate) change from baseline between 1 to 24 hours on Day 1 for the combination therapy", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}